Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Pharma Inc.

www.astellas.com

Latest From Astellas Pharma Inc.

MPM Raises $400m To Build Early-Stage Biotechs

The venture capitalist builds biotechs from scratch and with this latest fund, MPM is looking to add to its sector-leading record of 49 FDA-approved drugs and over 100 IPOs and acquisitions.

Financing ImmunoOncology

Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer

ASCO GU: Darolutamide is important for the company's oncology portfolio, but does it have enough to compete against J&J's Erleada and Pfizer/Astellas' Xtandi?

Cancer Gynecology & Urology

Affinivax’s MAPS Vaccine Technology Reaches Clinic In Under Five Years

Funded entirely by grants and partnerships to date, Affinivax’s pneumococcal vaccine candidate has begun a Phase I/II study less than five year’s after the biotech’s founding. Firm thinks its technology may eventually apply to immuno-oncology as well.

Vaccines Clinical Trials

Asia Executives On The Move: EdiGene, Teijin, Astellas

New round of funding allows EdiGene to hire a clinical development executive from Parexel, Teijin Pharma appoints a president, while Astellas has a new president of pharmaceutical technology.

Appointments Asia Pacific
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register